Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?

Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE:LLY) severe competition in the migraine treatment market. Eli Lilly and Co (NYSE:LLY) is acquiring CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) for $960 million and that will give it access to lasmiditan, a candidate for migraines that has been described as exhibiting a novel mechanism in battling the condition.

Though Eli Lilly and Co (NYSE:LLY) developed lasmiditan in-house, it decided in 2015 to license the drug to CoLucid. But now it wants it back as it presses for a leading position in migraine treatment.

“[lasmiditan] offers the potential clinical benefit from a more rapid and consistent administration of an existing triptan uniquely delivered via the pulmonary route,” Trbovich said in a note to investors.

Follow Lilly Eli & Co (NYSE:LLY)
Trade (NYSE:LLY) Now!

Inhaled Drugs Act More Rapidly

Despite lasmiditan being hailed as exhibiting a novel mechanism, inhaled migraine drugs such as Acorda’s CVT-427 have been proven to act faster than triptans. For instance, a study found that the Amgen, Inc. (NASDAQ:AMGN) inhaled DHE (dihydroergotamine) drug acted 30 minutes faster than control. Trbovich says Acorda Therapeutics Inc (NASDAQ:ACOR) could achieve a similar outcome from the Phase 3 trial of its candidate CVT-427.

Amgen got its hands on DHE in 2013 through acquisition of MAP Pharmaceuticals for $958 million.

15% Market Share

Though oral pills are the most widely used migraine drugs, non-oral drugs comprise about 15% of zolmitriptan dosed in the U.S., according to Trbovich. As such, Trbovich sees Acorda’s CVT-427 clipping away a meaningful share of the market from triptan drugs.

Trbovich further estimates CVT-427 could generate sales in the range of $50 to $200 million over the long-term.

Acorda’s CVT-427 is expected to complete Phase 2 clinical trials in 2018 and proceed to Phase 3 studies in 2019 to 2020. If the trials are successful, CVT-427 could launch in 2021 with patent protection stretching up to 2036.

Acorda Therapeutics Inc (NASDAQ:ACOR) shares have declined more than 45% over the last 12 months and fell 1.43% in the last session to end the day at $20.70.

Follow Acorda Therapeutics Inc (NASDAQ:ACOR)
Trade (NASDAQ:ACOR) Now!

Note: This article is written by Andy Parker and originally published at Market Exclusive.